CTAA vs DMII

ClearThink 1 Acquisition Corp. vs Drugs Made In America Acquisiti — Valuation Comparison 2026

CTAA

Blank Checks
ClearThink 1 Acquisition Corp.
Quality
4.2
out of 10
Value Trap
Price
$9.88
Last close
Models
7/13
Active
VS

DMII

Blank Checks
Drugs Made In America Acquisiti
Quality
4.6
out of 10
Value Trap
Price
$10.06
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType CTAA Fair ValueCTAA Upside DMII Fair ValueDMII Upside
Bayesian DCF Intrinsic $2.65 -73.2% $2.66 -73.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.87 -70.9% $3.65 -63.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $0.49 -95.1%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CTAA vs DMII — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CTAA vs DMII — Which Stock Is More Undervalued?

DMII scores higher with a 4.6/10 quality rating vs CTAA's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ClearThink 1 Acquisition Corp. (CTAA) and Drugs Made In America Acquisiti (DMII) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CTAA currently trades at $9.88 with a QOC of 4.2/10, while DMII trades at $10.06 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).